Review article: prognosis of hepatorenal syndrome--has it changed with current practice?

abstract：BACKGROUND:Some patients requiring acid suppression may be unable to take oral medications. AIM:To compare the gastric acid inhibition effects of lansoprazole 30 mg administered either intravenous or orally in erosive oesophagitis patients. METHODS:The study included 87 Helicobacter pylori-negative patients with eros...

journal_title：Alimentary pharmacology & therapeutics

authors： Kovacs TO,Lee CQ,Chiu YL,Pilmer BL,Metz DC

更新日期：2004-10-15 00:00:00

abstract：BACKGROUND:Helicobacter pylori infection is a major cause of the progress of gastric glandular atrophy, a high-risk background factor in the development of gastric cancer. Regression of gastric atrophy is critical to prevention of cancer by H. pylori eradication treatment. However, it is controversial whether gastric a...

journal_title：Alimentary pharmacology & therapeutics

authors： Sugiyama T,Sakaki N,Kozawa H,Sato R,Fujioka T,Satoh K,Sugano K,Sekine H,Takagi A,Ajioka Y,Takizawa T,H. Pylori Forum Gastritis Study Group.

更新日期：2002-04-01 00:00:00

abstract：BACKGROUND:There is a need for effective and inexpensive therapy for Helicobacter pylori with good patient compliance. AIM:To evaluate a simplified twice daily schedule for treating H. pylori. METHODS:Patients infected with H. pylori (positive by CLO- and 13C-urea breath tests [UBT]) and not previously treated with a...

journal_title：Alimentary pharmacology & therapeutics

authors： Mönkemüller KE,Hirschowitz BI

更新日期：1999-05-01 00:00:00

abstract：BACKGROUND:Non-alcoholic fatty liver disease is prevalent in affluent countries and is strongly associated with metabolic syndrome. AIM:To study the prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. METHODS:73 consecutive patients with biop...

journal_title：Alimentary pharmacology & therapeutics

authors： Wong VW,Hui AY,Tsang SW,Chan JL,Wong GL,Chan AW,So WY,Cheng AY,Tong PC,Chan FK,Sung JJ,Chan HL

更新日期：2006-10-15 00:00:00

abstract：:The effects of identical morning (08.05 hours) and evening (20.05 hours) meals on intragastric pH were compared in 12 healthy volunteers receiving gastric antisecretory medication. Dosing included continuous intravenous infusion ranitidine (50 mg bolus followed by 12.5 mg/h) or a matching placebo which were randomly a...

journal_title：Alimentary pharmacology & therapeutics

authors： Sanders SW,Moore JG,Day GM,Tolman KG

更新日期：1992-04-01 00:00:00

abstract：BACKGROUND:Proton pump inhibitor (PPI) use is associated with an increased risk of Clostridium difficile infection (CDI), though the mechanism is unclear. PPI induced alterations to the gut microbiome may facilitate the emergence of CDI, though the effects of PPIs on gut microbiota are not well characterised. [Correcti...

journal_title：Alimentary pharmacology & therapeutics

authors： Clooney AG,Bernstein CN,Leslie WD,Vagianos K,Sargent M,Laserna-Mendieta EJ,Claesson MJ,Targownik LE

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:Low bone mineral density (BMD) has been reported in both paediatric and adult patients with non-alcoholic fatty liver disease (NAFLD). The mechanisms behind the reduced BMD in NAFLD are still not completely understood. AIM:To provide a critical overview of the pathophysiological pathways linking NAFLD, redu...

journal_title：Alimentary pharmacology & therapeutics

authors： Yilmaz Y

更新日期：2012-08-01 00:00:00

abstract：BACKGROUND:Combined treatment using an acid-inhibiting drug with antibiotics can cure Helicobacter pylori infection. However, eradication rates are highly variable, especially if a proton pump inhibitor is used with amoxycillin. Therefore it is important to define factors/predictors of the clinical outcome. METHODS:In...

journal_title：Alimentary pharmacology & therapeutics

authors： Treiber G,Ammon S,Klotz U

更新日期：1997-08-01 00:00:00

abstract：:The effect of 7 days of oral dosing with 5 mg day-1 and 20 mg day-1 omeprazole on basal and pentagastrin-stimulated gastric acid output was studied in nine duodenal ulcer patients. Basal acid output measured 5-6 h post-dosing was decreased by a mean of 75% on 5 mg omeprazole and by 90% on 20 mg omeprazole (P less than...

journal_title：Alimentary pharmacology & therapeutics

authors： McLauchlan G,Crean GP,McColl KE

更新日期：1988-06-01 00:00:00

abstract：AIM:To evaluate the efficacy of omeprazole plus clarithromycin and furazolidone in Helicobacter pylori eradication and duodenal ulcer healing in Brazilian patients. METHODS:Forty H. pylori-positive patients with duodenal ulcer were randomized to receive 20 mg omeprazole o.m. or b.d. for 1 month plus 500 mg clarithromy...

journal_title：Alimentary pharmacology & therapeutics

authors： Dani R,Queiroz DM,Dias MG,Franco JM,Magalhães LC,Mendes GS,Moreira LS,De Castro LP,Toppa NH,Rocha GA,Cabral MM,Salles PG

更新日期：1999-12-01 00:00:00

abstract：BACKGROUND:In 1997-1998, 6127 asymptomatic children aged 2-4 years were screened for coeliac disease (CD) by anti-endomysium (EmA) testing in the Netherlands. After 6 (+/-2) months, biopsies were performed in 57 seropositive children; 31(54%) had villous atrophy, but 26 (46%), all HLA-DQ2/DQ8 positive, had normal histo...

journal_title：Alimentary pharmacology & therapeutics

authors： Hogen Esch CE,Csizmadia GD,van Hoogstraten IM,Schreurs MW,Mearin ML,von Blomberg BM

更新日期：2010-04-01 00:00:00

abstract：AIM:To determine whether misoprostol promotes the healing of non-steroidal anti-inflammatory drug-induced gastroduodenal lesions in a human experimental model. METHODS:Mucosal damage and healing of mucosal biopsy sites were assessed endoscopically in 10 healthy, Helicobacter pylori-negative volunteers with a normal in...

journal_title：Alimentary pharmacology & therapeutics

authors： Dorta G,Nicolet M,Vouillamoz D,Margalith D,Blum AL,Armstrong D,Saraga E

更新日期：1996-08-01 00:00:00

abstract：BACKGROUND:Helicobacter pylori eradication improves dyspeptic symptoms in 8%-10%, prevents peptic ulcer and may reduce the risk of gastric cancer. Availability of a high quality diagnostic test and an effective treatment makes population screening and eradication of Helicobacter pylori an attractive option. AIM:To eva...

journal_title：Alimentary pharmacology & therapeutics

authors： Høgh MB,Kronborg C,Hansen JM,Schaffalitzky de Muckadell OB

更新日期：2019-04-01 00:00:00

abstract：BACKGROUND:Infection is the most common cause of mortality in end-stage liver disease (ESLD). The impact of obesity on infection risk in ESLD is not established. AIM:To characterise the impact of obesity on infection risk in ESLD. METHODS:We evaluated the association between infection and obesity in patients with ESL...

journal_title：Alimentary pharmacology & therapeutics

authors： Sundaram V,Kaung A,Rajaram A,Lu SC,Tran TT,Nissen NN,Klein AS,Jalan R,Charlton MR,Jeon CY

更新日期：2015-12-01 00:00:00

abstract：BACKGROUND:There has been growing interest in the use of faecal microbiota transplantation (FMT) for the treatment of gastrointestinal and nongastrointestinal diseases. AIM:To review systematically the reported efficacy and safety of FMT in the management of gastrointestinal and nongastrointestinal disorders in adults...

journal_title：Alimentary pharmacology & therapeutics

authors： Sha S,Liang J,Chen M,Xu B,Liang C,Wei N,Wu K

更新日期：2014-05-01 00:00:00

abstract：BACKGROUND:Five oral nucleos(t)ide analogues are available to treat chronic hepatitis B (CHB). With the availability of newer agents, their efficacy on incidence of hepatocellular carcinoma (HCC) is not well described. AIM:To determine the efficacy of oral anti-viral agents in reducing HCC risk in relationship with ot...

journal_title：Alimentary pharmacology & therapeutics

authors： Singal AK,Salameh H,Kuo YF,Fontana RJ

更新日期：2013-07-01 00:00:00

abstract：:The risk of colorectal cancer for any patient with ulcerative colitis is estimated to be 2% after 10 years, 8% after 20 years and 18% after 30 years of disease. The relative risk of colorectal cancer in Crohn's colitis is approximately 5.6 and should raise the same concerns as in ulcerative colitis. Risk factors for c...

journal_title：Alimentary pharmacology & therapeutics

authors： Eaden J

更新日期：2004-10-01 00:00:00

abstract：BACKGROUND:(13)CO(2) is produced on metabolism of (13)C-labelled-pantoprazole ([(13)C]-pantoprazole) by CYP2C19. AIM:To investigate whether the [(13)C]-pantoprazole breath test can predict CYP2C19 status and efficacy of proton pump inhibitors (PPIs) in Japanese. METHODS:We classified 110 healthy volunteers as rapid m...

journal_title：Alimentary pharmacology & therapeutics

authors： Furuta T,Kodaira C,Nishino M,Yamade M,Sugimoto M,Ikuma M,Hishida A,Watanabe H,Umemura K

更新日期：2009-08-01 00:00:00

abstract：BACKGROUND:HCV-TARGET is a longitudinal observational study of chronic hepatitis C virus (HCV) patients treated with direct-acting anti-viral agents (DAAs) in a US consortium of 90 academic and community medical centres. AIM:To assess utilisation of response-guided therapy (RGT) and sustained virological response (SVR...

journal_title：Alimentary pharmacology & therapeutics

authors： Sterling RK,Kuo A,Rustgi VK,Sulkowski MS,Stewart TG,Fenkel JM,El-Genaidi H,Mah'moud MA,Abraham GM,Stewart PW,Akushevich L,Nelson DR,Fried MW,Di Bisceglie AM

更新日期：2015-04-01 00:00:00

abstract：BACKGROUND:Ustekinumab is a monoclonal antibody targeting interleukins-12 and -23, with efficacy in Crohn's disease (CD) demonstrated in clinical trials. AIM:To assess the real-world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in medically-refractory CD. METHODS:A r...

journal_title：Alimentary pharmacology & therapeutics

authors： Ma C,Fedorak RN,Kaplan GG,Dieleman LA,Devlin SM,Stern N,Kroeker KI,Seow CH,Leung Y,Novak KL,Halloran BP,Huang VW,Wong K,Blustein PK,Ghosh S,Panaccione R

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:Pantoprazole is a new substituted benzimidazole that blocks the H+/K(+)-ATPase in the gastric mucosa and thus inhibits acid secretion. METHODS:Efficacy and tolerability of pantoprazole (40 mg at breakfast) and ranitidine (300 mg at bedtime) in the treatment of uncomplicated acute duodenal ulcer were compare...

journal_title：Alimentary pharmacology & therapeutics

authors： Judmaier G,Koelz HR

更新日期：1994-02-01 00:00:00

abstract：BACKGROUND:Gastric cancer can be divided into cardia and noncardia gastric adenocarcinoma (NCGA). Non cardia gastric cancer is a disease that has declined in global incidence but has remained as an extremely lethal cancer. AIM:To review recent advances in epidemiology and strategies in prevention of non cardia gastric...

journal_title：Alimentary pharmacology & therapeutics

authors： Fock KM

更新日期：2014-08-01 00:00:00

abstract：BACKGROUND:Anti-TNFα agents have revolutionised management of chronic inflammatory diseases. Paradoxically, these agents might provoke development of de novo autoimmune diseases. AIM:To examine whether there is an increased risk of developing Crohn's disease (CD) and ulcerative colitis (UC) while under treatment with ...

journal_title：Alimentary pharmacology & therapeutics

authors： Korzenik J,Larsen MD,Nielsen J,Kjeldsen J,Nørgård BM

更新日期：2019-08-01 00:00:00

abstract：BACKGROUND:Morphological, haemodynamic and clinical stages of cirrhosis have been proposed, although no definite staging system is yet accepted for clinical practice. AIM:To investigate whether clinical complications of cirrhosis may define different prognostic disease stages. METHODS:Analysis of the database from a ...

journal_title：Alimentary pharmacology & therapeutics

authors： D'Amico G,Pasta L,Morabito A,D'Amico M,Caltagirone M,Malizia G,Tinè F,Giannuoli G,Traina M,Vizzini G,Politi F,Luca A,Virdone R,Licata A,Pagliaro L

更新日期：2014-05-01 00:00:00

abstract：BACKGROUND:Recently, the therapeutic landscape with regard to anti-HCV therapy has changed dramatically. The new directly acting anti-virals (DAAs) have demonstrated improved sustained virological response (SVR) compared with pegylated-interferon and ribavirin. AIM:To examine and present the latest data with regard to...

journal_title：Alimentary pharmacology & therapeutics

authors： Joshi D,Carey I,Agarwal K

更新日期：2013-04-01 00:00:00

abstract：:More than 15 years after the launch of omeprazole in 1988, proton-pump inhibitors remain central to the management of acid-suppression disorders and are unchallenged with regard to their efficacy and popularity among doctors and patients. They are considered safe despite early concerns about the possibility of an asso...

journal_title：Alimentary pharmacology & therapeutics

authors： Raghunath AS,O'Morain C,McLoughlin RC

更新日期：2005-08-01 00:00:00

abstract：BACKGROUND:Symptoms of lactose intolerance are often attributed to lactose malabsorption but, as this relationship has not been demonstrated when a small dose of lactose similar to that contained in one cup of milk is ingested by intolerant patients, psychological factors may play a role in altered symptom perception. ...

journal_title：Alimentary pharmacology & therapeutics

authors： Tomba C,Baldassarri A,Coletta M,Cesana BM,Basilisco G

更新日期：2012-10-01 00:00:00

abstract：BACKGROUND:Therapeutic drug monitoring is a powerful strategy known to improve the clinical outcomes and to optimise the healthcare resources in the treatment of autoimmune diseases. Currently, most of the methods commercially available for the quantification of infliximab (IFX) are ELISA-based, with a turnaround time ...

journal_title：Alimentary pharmacology & therapeutics

authors： Afonso J,Lopes S,Gonçalves R,Caldeira P,Lago P,Tavares de Sousa H,Ramos J,Gonçalves AR,Ministro P,Rosa I,Vieira AI,Dias CC,Magro F,Portuguese IBD Study Group (GEDII).

更新日期：2016-10-01 00:00:00

abstract：BACKGROUND:The diagnosis of covert hepatic encephalopathy (CHE) by means of portosystemic encephalopathy syndrome (PSE) test is costly and therefore infrequently performed. AIM:To determine the ability of critical flicker frequency (CFF) alone or in combination with laboratory findings, as an initial test to pre-selec...

journal_title：Alimentary pharmacology & therapeutics

authors： Greinert R,Ripoll C,Hollenbach M,Zipprich A

更新日期：2016-09-01 00:00:00

abstract：BACKGROUND:Serum hepatitis B virus (HBV) RNA may reflect intrahepatic HBV replication. Novel anti-viral drugs have shown potent HBV RNA decline without concomitant hepatitis B surface antigen (HBsAg) decrease. How this relates to off-treatment response is yet unclear. AIM:To study the degree of on-treatment viral anti...

journal_title：Alimentary pharmacology & therapeutics

authors： Brakenhoff SM,de Man RA,Boonstra A,van Campenhout MJH,de Knegt RJ,van Bömmel F,van der Eijk AA,Berg T,Hansen BE,Janssen HLA,Sonneveld MJ

更新日期：2021-01-01 00:00:00